Publication Name	World Journal of Clinical Cases
Manuscript ID	56177
Country	China

Received	2020-05-08 09:19
Peer-Review Started	2020-05-08 09:19
To Make the First Decision
Return for Revision	2020-06-07 23:47
Revised	2020-06-08 13:51
Second Decision	2020-08-05 08:17
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-08-05 23:13
Articles in Press	2020-08-05 23:13
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-08-17 05:59
Typeset the Manuscript	2020-08-29 15:17
Publish the Manuscript Online	2020-09-04 08:47

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Retrospective Study
Article Title	Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
Manuscript Source	Unsolicited Manuscript
All Author List	Jia Zeng, Ming-Hui Xie, Jing Yang, Sheng-Wu Chao and Er-Li Xu
ORCID	Author(s) ORCID Number Jia Zeng http://orcid.org/0000-0001-5201-4526 Ming-Hui Xie http://orcid.org/0000-0002-3001-5827 Jing Yang http://orcid.org/0000-0002-3244-0971 Sheng-Wu Chao http://orcid.org/0000-0002-3031-8670 Er-Li Xu http://orcid.org/0000-0001-9453-0801
Funding Agency and Grant Number
Corresponding Author	Er-Li Xu, BMed, Associate Chief Physician, Department of Aviation Disease, Naval Medical Center of PLA, No. 338 Huaihai West Road, Changning District, Shanghai 200052, China. yijiacheng455@163.com
Key Words	COVID-19; Cytokine storm; Tocilizumab; Interleukin-6; ;
Core Tip	It is effective to treat with coronavirus disease 2019 (COVID-19) patients by using tocilizumab against IL-6, but it cannot completely inhibit the inflammation and cytokine storm in all patients with COVID-19. In the clinical treatment of patients, we should pay attention to the timing of drug use and other adjuvant treatments.
Publish Date	2020-09-04 08:47
Citation	Zeng J, Xie MH, Yang J, Chao SW, Xu EL. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients. World J Clin Cases 2020; 8(17): 3763-3773
URL	https://www.wjgnet.com/2307-8960/full/v8/i17/3763.htm
DOI	https://dx.doi.org/10.12998/wjcc.v8.i17.3763

Full Article (PDF)	WJCC-8-3763.pdf
Full Article (Word)	WJCC-8-3763.docx
Manuscript File	56177-Review-Webster J.docx
Answering Reviewers	56177-Answering reviewers.pdf
Audio Core Tip	56177-Audio core tip.aac
Biostatistics Review Certificate	56177-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	56177-Conflict-of-interest statement.pdf
Copyright License Agreement	56177-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	56177-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	56177-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	56177-Language certificate.pdf
Peer-review Report	56177-Peer-review(s).pdf
Scientific Misconduct Check	56177-Scientific misconduct check.pdf
Scientific Editor Work List	56177-Scientific editor work list.pdf